ReviewNature reviews. Cardiology2016
Global cardiovascular protection in chronic kidney disease.
Review in Nature reviews. Cardiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 46 citations in OpenAlex.
- Correlation between albumin-bilirubin score and comorbidity of cardiovascular disease and chronic kidney disease: insights from NHANES 2011-2018.European journal of medical research · 2026Article
- Organ cross-talk: molecular mechanisms, biological functions, and therapeutic interventions for diseases.Signal transduction and targeted therapy · 2026Review
- Angiotensin-Converting Enzyme Inhibitors to Prevent Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: Scientific Speculation or an Opportunity to Improve Real Clinical Practice?International journal of molecular sciences · 2025Review
- Finerenone Versus Placebo on Renal Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Social Determinants of Health in the Development of Cardiovascular-kidney-metabolic Syndrome.Reviews in cardiovascular medicine · 2025Review
- Kidney function and cardiovascular diseases: a large-scale observational and Mendelian randomization study.Frontiers in immunology · 2023Article
- Mineralocorticoid receptor antagonists for cardioprotection in chronic kidney disease: a step into the future.Journal of human hypertension · 2022Review
- Fat Mass Index Associated with Blood Pressure Abnormalities in Children with Chronic Kidney Disease.Children (Basel, Switzerland) · 2021Article
- The need for a cardionephrology subspecialty.Clinical kidney journal · 2021Article
- Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets.Frontiers in physiology · 2021Review
- SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives.Journal of human hypertension · 2021Review
- Cardiovascular Disease Risk in Children With Chronic Kidney Disease: Impact of Apolipoprotein C-II and Apolipoprotein C-III.Frontiers in pediatrics · 2021Article
- Article
- Association between Acrylamide Metabolites and Cardiovascular Risk in Children With Early Stages of Chronic Kidney Disease.International journal of molecular sciences · 2020Article
- Medication burden and inappropriate prescription risk among elderly with advanced chronic kidney disease.BMC geriatrics · 2020Article
- Alisol B 23-acetate attenuates CKD progression by regulating the renin-angiotensin system and gut-kidney axis.Therapeutic advances in chronic disease · 2020Article
- Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints.European heart journal · 2019Article
- Microalbuminuria and cardiorenal risk: old and new evidence in different populations.F1000Research · 2019Review
- The impact of antihypertensives on kidney disease.F1000Research · 2017Review
- New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney Disease.Oxidative medicine and cellular longevity · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development and progression of cardiovascular disease (CVD) and renal disorders are very closely related. In patients with chronic kidney disease (CKD), therapies proven to protect the cardiovascular and renal systems simultaneously are generally used only at low doses or not at all. In particular, patients with CKD who receive angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers, or mineralocorticoid-receptor antagonists (MRAs) often do not experience complete blockade of the renin-angiotensin-aldosterone system, primarily owing to the risk of hyperkalaemia. In this Review, we provide an overview of the available treatments required for adequate cardiorenal protection in patients with CKD. Drugs such as β-blockers that interfere with renin secretion will be discussed, in addition to agents that can prevent hyperkalaemia, such as potassium binders and nonsteroidal MRAs. Furthermore, the current literature on the role of statins, in addition to new compounds and dosing recommendations for the treatment of patients with CKD will also be reviewed. Further studies with these new compounds and doses are needed to ascertain whether these approaches can improve the long-term cardiovascular and renal prognosis in patients with CKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.